Literature DB >> 22526161

MicroRNA-21 correlates with tumorigenesis in malignant peripheral nerve sheath tumor (MPNST) via programmed cell death protein 4 (PDCD4).

Satoru Itani1, Toshiyuki Kunisada, Yuki Morimoto, Aki Yoshida, Tsuyoshi Sasaki, Sachio Ito, Mamoru Ouchida, Shinsuke Sugihara, Kenji Shimizu, Toshifumi Ozaki.   

Abstract

PURPOSE: We investigated the miRNA profile in peripheral nerve tumors and clarified the involvement of miRNA in the development and progression of MPNST in comparison with neurofibroma (NF). In addition, we attempted to seek associations between the miRNA and their potential targets in MPNST.
METHODS: Global miRNA expression profiling was investigated for clinical samples of 6 MPNSTs and 6 NFs. As detected by profiling analysis, the expressions of miR-21 in clinical samples of 12 MPNSTs, 11 NFs, and 5 normal nerves, and 3 MPNST cell lines were compared using quantitative real-time reverse transcription PCR. MPNST cell line (YST-1) was transfected with miR-21 inhibitor to study its effects on cell proliferation, caspase activity, and the expression of miR-21 targets.
RESULTS: Analysis of miRNA expression profiles in MPNST and NF revealed significantly altered expression levels of nine miRNAs, one of those, miR-21, and its putative target, programmed cell death protein 4 (PDCD4), were selected for further studies. miR-21 expression level in MPNST was significantly higher than that in NF (P < 0.05). In MPNST cells, transfection of miR-21 inhibitor significantly increased caspase activity (P < 0.01), significantly suppressed cell growth (P < 0.05), and upregulated protein level of PDCD4, indicating that miR-21 inhibitor could induce cell apoptosis of MPNST cells.
CONCLUSIONS: These results suggest that miR-21 plays an important role in MPNST tumorigenesis and progression through its target, PDCD4. MiR-21 and PDCD4 may be candidate novel therapeutic targets against the development or progression of MPNSTs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22526161     DOI: 10.1007/s00432-012-1223-1

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  49 in total

Review 1.  The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network.

Authors:  Lakshmanane Boominathan
Journal:  Cancer Metastasis Rev       Date:  2010-12       Impact factor: 9.264

2.  MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML.

Authors:  Sukanya Suresh; Lynn McCallum; Wanhua Lu; Noureddine Lazar; Bernard Perbal; Alexandra E Irvine
Journal:  J Cell Commun Signal       Date:  2011-06-03       Impact factor: 5.782

3.  Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation.

Authors:  G P Nielsen; A O Stemmer-Rachamimov; Y Ino; M B Moller; A E Rosenberg; D N Louis
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

4.  MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma.

Authors:  Bjørn Helge Haug; Jørn R Henriksen; Jochen Buechner; Dirk Geerts; Ellen Tømte; Per Kogner; Tommy Martinsson; Trond Flægstad; Baldur Sveinbjørnsson; Christer Einvik
Journal:  Carcinogenesis       Date:  2011-05-13       Impact factor: 4.944

5.  Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance.

Authors:  Yue Chen; Yongxi Song; Zhenning Wang; Zhenyu Yue; Huimian Xu; Chengzhong Xing; Zhuangkai Liu
Journal:  J Gastrointest Surg       Date:  2010-04-27       Impact factor: 3.452

6.  Biallelic inactivation of TP53 rarely contributes to the development of malignant peripheral nerve sheath tumors.

Authors:  R A Lothe; B Smith-Sørensen; M Hektoen; A E Stenwig; N Mandahl; G Saeter; F Mertens
Journal:  Genes Chromosomes Cancer       Date:  2001-02       Impact factor: 5.006

7.  MicroRNA-21 overexpression contributes to vestibular schwannoma cell proliferation and survival.

Authors:  Joseph A Cioffi; Wei Ying Yue; Sabrina Mendolia-Loffredo; Kameron R Hansen; P Ashley Wackym; Marlan R Hansen
Journal:  Otol Neurotol       Date:  2010-12       Impact factor: 2.311

8.  Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells.

Authors:  Lisa B Frankel; Nanna R Christoffersen; Anders Jacobsen; Morten Lindow; Anders Krogh; Anders H Lund
Journal:  J Biol Chem       Date:  2007-11-08       Impact factor: 5.157

9.  Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells.

Authors:  Bo Song; Yuan Wang; Matthew A Titmus; Galina Botchkina; Andrea Formentini; Marko Kornmann; Jingfang Ju
Journal:  Mol Cancer       Date:  2010-04-30       Impact factor: 27.401

10.  Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis.

Authors:  Olubunmi Afonja; Dominique Juste; Sharmistha Das; Sachiko Matsuhashi; Herbert H Samuels
Journal:  Oncogene       Date:  2004-10-21       Impact factor: 9.867

View more
  16 in total

1.  Identification of serum microRNAs in genome-wide serum microRNA expression profiles as novel noninvasive biomarkers for malignant peripheral nerve sheath tumor diagnosis.

Authors:  Yuxiong Weng; Yanhua Chen; Jianghai Chen; Yutian Liu; Tengfei Bao
Journal:  Med Oncol       Date:  2013-03-13       Impact factor: 3.064

2.  Downregulation of microRNA-182 inhibits cell growth and invasion by targeting programmed cell death 4 in human lung adenocarcinoma cells.

Authors:  Min Wang; Yuanyuan Wang; Wenqiao Zang; Huaqi Wang; Heying Chu; Ping Li; Min Li; Guojun Zhang; Guoqiang Zhao
Journal:  Tumour Biol       Date:  2013-07-23

Review 3.  MicroRNA-mediated gene regulations in human sarcomas.

Authors:  Subbaya Subramanian; Reena V Kartha
Journal:  Cell Mol Life Sci       Date:  2012-08-25       Impact factor: 9.261

Review 4.  Neurofibromin and suppression of tumorigenesis: beyond the GAP.

Authors:  Juan Mo; Stefanie L Moye; Renee M McKay; Lu Q Le
Journal:  Oncogene       Date:  2022-01-23       Impact factor: 8.756

Review 5.  MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics.

Authors:  Jyotika Varshney; Subbaya Subramanian
Journal:  Front Mol Biosci       Date:  2015-06-17

Review 6.  MicroRNAs in soft tissue sarcomas: overview of the accumulating evidence and importance as novel biomarkers.

Authors:  Tomohiro Fujiwara; Toshiyuki Kunisada; Ken Takeda; Koji Uotani; Aki Yoshida; Takahiro Ochiya; Toshifumi Ozaki
Journal:  Biomed Res Int       Date:  2014-08-04       Impact factor: 3.411

Review 7.  MicroRNAs: emerging driver of cancer perineural invasion.

Authors:  Mei Zhang; Hong-Chun Xian; Li Dai; Ya-Ling Tang; Xin-Hua Liang
Journal:  Cell Biosci       Date:  2021-06-29       Impact factor: 7.133

8.  Feedback regulations of miR-21 and MAPKs via Pdcd4 and Spry1 are involved in arsenite-induced cell malignant transformation.

Authors:  Lu Shen; Min Ling; Yuan Li; Yuan Xu; Yun Zhou; Jing Ye; Ying Pang; Yue Zhao; Rongrong Jiang; Jianping Zhang; Qizhan Liu
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240

Review 9.  An emerging role for microRNAs in NF1 tumorigenesis.

Authors:  Ashni Sedani; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2012-11-17       Impact factor: 4.639

Review 10.  Regulation of gene expression by microRNA in HCV infection and HCV-mediated hepatocellular carcinoma.

Authors:  Priyanka Gupta; Murray J Cairns; Nitin K Saksena
Journal:  Virol J       Date:  2014-04-01       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.